Compare Becton Dickinson and Co (BDX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Xpeng Inc - ADR — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Xpeng Inc - ADR trades at $13.83 (market cap $12.77B). The key difference: Becton Dickinson and Co is far larger — about 3.3× Xpeng Inc - ADR's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| BDX | XPEV | |
|---|---|---|
Market Cap | $41.51B | $12.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $28.07 |
52-Week Low | $135.49 | $12.09 |
Enterprise Value | $57.97B | $14.88B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
XPeng (XPEV) trades at $12.95, down 0.61% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 deliveries of 103,295 vehicles, beating guidance, but continues to post net losses with a -3.06% margin. Revenue grew to $76.72B in 2025, though cash flow from operations was negative $2.01B in 2024. Analyst sentiment is mixed with 64.7% buy ratings.
The outlook hinges on XPeng's ability to achieve profitability amid expansion. Opportunities include new model launches and international growth, but risks persist from intense EV competition and ongoing cash burn. The stock's valuation at P/S of 1.14 may attract value investors if margins improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
